Priovant nabs first FDA approval for targeted tablet in dermatomyositis

FDA approves Priovant's Lisraya for rare inflammatory disorder dermatomyositis

The FDA approved Roivant Sciences subsidiary Priovant Therapeutics' Lisraya as a once-daily pill treatment for dermatomyositis, a rare inflammatory disorder. The drug was licensed from Pfizer.